BioXcel Therapeutics, Inc.
BTAI evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BTAI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BTAI
BioXcel Therapeutics, Inc. (BTAI) is a biopharmaceutical company leveraging an AI-driven platform to develop and commercialize treatments for neuroscience and immuno-oncology, with a lead candidate (BXCL501/igalmi) for acute agitation and a PDUFA date of November 14, 2026.
Key risk: Limited cash runway
BioSniper Score
Based on 6 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 14 clinical trials · 1 catalyst for BioXcel Therapeutics, Inc..
BioXcel Therapeutics, Inc. (BTAI) is a biopharmaceutical company leveraging an AI-driven platform to develop and commercialize treatments for neuroscience and immuno-oncology, with a lead candidate (BXCL501/igalmi) for acute agitation and a PDUFA date of November 14, 2026.
- Cash and equivalents of $13.8M as of 2026-06-30 [sec].
- Total revenue of $0.2M and net loss of -$14.7M for the six months ended June 30, 2026 [sec].
- Shareholders' equity of -$107.7M and total debt of $208.9M as of 2026-06-30 [sec].
- Lead product candidate is BXCL501 (igalmi), an orally dissolving film for acute agitation, with a PDUFA date of November 14, 2026 [upcoming catalysts].
- The company has implemented workforce reductions and a clinical reprioritization to extend cash runway and focus on BXCL501 development [sec_mda · as of 2026-03-27].
What works
- Proprietary AI platform designed to reduce therapeutic development costs and accelerate timelines by repurposing approved drugs for new indications [sec_mda · as of 2026-08-13].
- Lead candidate BXCL501 (igalmi) is approaching a PDUFA decision on November 14, 2026, representing a potential near-term catalyst [upcoming catalysts].
- Management has taken proactive restructuring steps (workforce reductions, clinical reprioritization) to preserve cash and focus resources on core programs [sec_mda · as of 2026-03-27].
What to weigh
- Significant accumulated losses and negative shareholders' equity (-$107.7M as of 2026-06-30) indicate ongoing financial strain [sec].
- High debt burden of $208.9M as of 2026-06-30, with substantial repayment obligations that may limit financial flexibility [sec].
- Cash runway is limited ($13.8M as of 2026-06-30), and the company acknowledges it may use available capital sooner than expected, requiring additional funding [sec_mda · as of 2026-08-13].
- No approved products or recurring revenue; total revenue was only $0.2M for the six months ended June 30, 2026 [sec].
Catalyst timeline
- 2026-11-14 · PDUFA · igalmi — FDA decision date for BXCL501 (igalmi) for acute agitation; approval would be a major milestone, while a delay or rejection could significantly impact the company's outlook.
Risks & what to watch (4)›
Key risks
- Limited cash runway — Cash of $13.8M as of 2026-06-30 may be insufficient to fund operations without additional financing [sec].
- High debt and negative equity — Total debt of $208.9M and negative shareholders' equity of -$107.7M as of 2026-06-30 create financial vulnerability [sec].
- Dependence on BXCL501 approval — The company's near-term prospects hinge on FDA approval of BXCL501 (igalmi) by the November 14, 2026 PDUFA date [upcoming catalysts].
- No approved products or revenue — Total revenue was only $0.2M for the six months ended June 30, 2026, with no approved products generating sales [sec].
What to watch
- FDA decision on BXCL501 (igalmi) PDUFA date of November 14, 2026 [upcoming catalysts].
- Ability to raise additional capital given limited cash runway and high debt [sec_mda · as of 2026-08-13].
- Progress of clinical development for BXCL501 and any other pipeline programs [sec_mda · as of 2026-08-13].
- Any further restructuring or strategic alternatives to preserve cash [sec_mda · as of 2026-03-27].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run BioXcel Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BioXcel Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
9.0 months
OCF -$6M · Net income -$15M
Lead: Phase 3
2 candidates
1 upcoming, next in ~76d
0 buys · 4 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
39
Total value held
$8.3M
| Holder | Shares | Value |
|---|---|---|
| millennium management llc | 1,936,760 | $2.6M |
| armistice capital, llc | 1,910,076 | $2.6M |
| oaktree capital management lp | 723,564 | $970K |
| vanguard capital management llc | 414,678 | $556K |
| geode capital management, llc | 230,168 | $309K |
| jones financial companies lllp | 131,789 | $166K |
| man group plc | 96,473 | $129K |
| state street corp | 92,118 | $123K |
| fmr llc | 90,300 | $121K |
| oaktree fund advisors, llc | 85,826 | $115K |
Showing top 10 of 39 institutional holders of BioXcel Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 16.0%
- Days to cover
- 4.0
- Shares short
- 4,243,441
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BTAI short interestGovernance
Frequently asked questions
What is the AI investment thesis for BioXcel Therapeutics, Inc.?
BioXcel Therapeutics, Inc. (BTAI) is a biopharmaceutical company leveraging an AI-driven platform to develop and commercialize treatments for neuroscience and immuno-oncology, with a lead candidate (BXCL501/igalmi) for acute agitation and a PDUFA date of November 14, 2026.
What is BioXcel Therapeutics, Inc.'s lead drug candidate?
BioXcel Therapeutics, Inc.'s most advanced tracked candidate is bxcl501 (Phase 2) for Agitation,Psychomotor; Agitation.
What is BioXcel Therapeutics, Inc.'s next catalyst?
BioXcel Therapeutics, Inc.'s next tracked catalyst is a PDUFA event — "PDUFA Date: igalmi" — expected November 14, 2026.
Who is the CEO of BioXcel Therapeutics, Inc.?
Dr. Vimal D. Mehta Ph.D. is the chief executive officer of BioXcel Therapeutics, Inc. (BTAI).
Where is BioXcel Therapeutics, Inc. headquartered?
BioXcel Therapeutics, Inc. (BTAI) is headquartered in New Haven, CT, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.